Psyence Biomedical Ltd (NASDAQ: PBM), an associate of Psyence Group Inc, has announced the recruitment of Empax Center in Perth, Australia, as the second clinical trial site for its ongoing Phase IIb clinical trial. This trial is evaluating nature-derived psilocybin as a potential treatment for Adjustment Disorder in palliative care.
Trial Expansion and Expertise
The addition of Empax Center, a facility specializing in mental health treatments including psychedelic-assisted therapies, is expected to expedite patient enrollment. Dr. Clive Ward-Able, Medical Director of Psyence Biomed, emphasized the importance of this expansion, stating that it "helps position us to enroll this important study as quickly and efficiently as possible."
Anticipated Timeline and Data
The affiliated trial sites are preparing to begin screening patients, with the first subject anticipated to be randomized into the study in early December. Psyence Biomed anticipates topline data from the Phase IIb trial in the second half of 2025. Positive results could pave the way for pivotal registrational studies.
About Empax Center
Empax Center is dedicated to delivering emerging treatments for serious mental health conditions. The center is staffed by experienced mental health professionals, including authorized prescribers of psychedelic-assisted therapies in Australia, supporting both research and client care.
About Psyence Group and Psyence Biomed
Psyence Group Inc (CSE: PSYG) focuses on natural psychedelics. Psyence Biomed (NASDAQ: PBM) is focused on developing botanical psilocybin-based medicines for psychological trauma and its mental health consequences within palliative care.
